2026-01-28 - Analysis Report
**Stock Analysis Report for Novo Nordisk (NVO)**

**Company Overview:** 
Novo Nordisk is a Danish multinational pharmaceutical company specializing in diabetes care and obesity management.

**Return Rate Comparison:**

|  | NVO (Rate) | VOO (Rate_vs) | Divergence | Relative Divergence |
| --- | --- | --- | --- | --- |
| Cumulative Return | 97.22% | 128.51% | -31.29% | 14.00% |

Novo Nordisk's cumulative return lags behind the S&P 500 (VOO) by 31.29% with a relatively high divergence of 14.00%.

**Alpha, Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta | Cap(B) |
| --- | --- | --- | --- | --- | --- |
| 2016-2018 | 4.0% | 18.2% | -5.0% | 0.8 | 102.4B |
| 2017-2019 | 54.0% | 14.1% | 29.0% | 0.6 | 128.6B |
| 2018-2020 | 23.0% | 23.6% | -1.0% | 0.6 | 155.2B |
| 2019-2021 | 118.0% | 23.6% | 54.0% | 0.6 | 248.8B |
| 2020-2022 | 116.0% | 23.6% | 111.0% | 0.6 | 300.7B |
| 2021-2023 | 208.0% | 19.9% | 190.0% | 0.5 | 459.7B |
| 2022-2024 | 78.0% | 41.1% | 48.0% | 0.5 | 382.2B |
| 2023-2025 | -98.0% | 67.0% | -174.0% | 0.7 | 226.1B |

**Recent Stock Price Fluctuations:**

|  | Last-Market | 5-day SMA | 20-day SMA | 60-day SMA |
| --- | --- | --- | --- | --- |
| Close | $62.89 | $62.14 | $57.96 | $51.65 |
| Price Change | -1.7% |  N/A  |  N/A  |  N/A  |

**RSI, PPO, and Market Risk Indicator (MRI):**

|  |  |
| --- | --- |
| RSI (Relative Strength Index) | 66.32 |
| PPO (Percentage Price Oscillator) | 0.45 |
| Market Risk Indicator (MRI) | 0.70 (Medium Risk) |
| Recent (20 days) relative divergence change | +1.30 |
| 7-day Rank change | +1 |
| 7-day Dynamic Expected Return change | +655.50 |
| Reflecting Fluctuation Issue | Sharp Decline (-1.7%) over the last day |

**Expected Return:**

|  |  |
| --- | --- |
| Expected Return (%) | 918.70% |

**Analyst Opinions:**

* Analyst Consensus:
	+ Key: Buy
	+ Mean (1=StrongBuy~5=Sell): 2.38 (~Buy)
	+ Opinions: 11
	+ Target Price (avg/high/low): 60.01 / 75.99 / 43.19

**Comprehensive Analysis:**

Based on the provided data, Novo Nordisk's stock performance has been relatively stable, with a cumulative return of 97.22% compared to the S&P 500's 128.51%. However, the stock's recent price decline by 1.7% and the relatively high market risk indicator (MRI) of 0.70 suggest that the stock may be at risk. 

Recent news and analyst opinions indicate potential for growth, with expected returns as high as 918.70%. However, it's essential to monitor the stock's performance and adjust investment strategies accordingly.

**Significant Events:**

* Prediction: This Healthcare Stock Could Soar by 40% in 2026 - The Motley Fool
* Novo Nordisk Vs. Eli Lilly: The Tide May Be Turning For The Underdog (NYSE:NVO) - Seeking Alpha
* Novo Nordisk Regains Spotlight with New Oral Formulation, Stock May Have 40% Upside Potential - NAI500
* Novo Nordisk A/S $NVO Shares Bought by Markel Group Inc. - MarketBeat
* 1 Pharmaceutical Stock Set to Rebound in 2026 - The Globe and Mail
* Oral Wegovy Is Off To An Astronomical Launch. Will It Save Novo Nordisk Stock? - Investor's Business Daily

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.